Results 91 to 100 of about 53,470 (300)

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

The independent contribution of executive functions to health related quality of life in older women

BMC Geriatrics, 2010
Background Cognition is a multidimensional construct and to our knowledge, no previous studies have examined the independent contribution of specific domains of cognition to health related quality of life.
Marra Carlo A, Davis Jennifer C, Najafzadeh Mehdi, Liu-Ambrose Teresa   +3 more
doaj   +1 more source

Economic evaluation of laparoscopic surgery for colorectal cancer [PDF]

, 2007
Objectives: To assess the cost-effectiveness of laparoscopic surgery compared with open surgery for the treatment of colorectal cancer. Methods: A Markov model was developed to model cost-effectiveness over 25 years.
Aberdeen Health Technology Assessment Group, De Verteuil, Robyn, Hernández, Rodolfo Andrés, Vale, Luke David   +3 more
core   +1 more source

Preferences, needs and QALYs. [PDF]

Journal of Medical Ethics, 1996
Quality Adjusted Life Years (QALYs) have become a household word among health economists. Their use as a means of comparing the value of health programmes and medical interventions has stirred up controversy in the medical profession and the academic community.
openaire   +3 more sources

Cost effectiveness analysis for commonly used human cell and tissue products in the management of diabetic foot ulcers

Health Science Reports
Background and Aims This study considers the cost‐effectiveness of commonly used cellular, acellular, and matrix‑like products (CAMPs) of human origin also known as human cell and tissue products (HCT/Ps) in the management of diabetic foot ulcers ...
Leo M. Nherera, Jaideep Banerjee
doaj   +1 more source

Health Economic Evaluation of Patients With Colorectal Liver Metastases Randomized to ALPPS or TSH: Analysis From the LIGRO Trial

Annals of Surgery Open
Objective:. This is a preplanned, health economic evaluation from the LIGRO trial. One hundred patients with colorectal liver metastases (CRLM) and standardized future liver remnant
Kristina Hasselgren, MD, PhD, Martin Henriksson, PhD, Bård I. Røsok, MD, PhD, Peter N. Larsen, MD, PhD, Ernesto Sparrelid, MD, PhD, Gert Lindell, MD, PhD, Nicolai A. Schultz, MD, PhD, Bjorn A. Bjørnbeth, MD, PhD, Bengt Isaksson, MD, PhD, Magnus Rizell, MD, PhD, Anna Lindhoff Larsson, RN, Per Sandström, MD, PhD, Bergthor Björnsson, MD, PhD   +12 more
doaj   +1 more source

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundA validated prediction model estimates the absolute benefit of intensive versus standard lipid‐lowering therapy (LLT) with statins on next major cardiovascular events for individual patients with coronary artery disease.
Manon C. Stam‐Slob, Yolanda van der Graaf, Jacoba P. Greving, Jannick A.N. Dorresteijn, Frank L.J. Visseren   +4 more
doaj   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Severity as a Priority Setting Criterion: Setting a Challenging Research Agenda [PDF]

, 2019
Priority setting in health care is ubiquitous and health authorities are increasingly recognising the need for priority setting guidelines to ensure efficient, fair, and equitable resource allocation. While cost-effectiveness concerns
Barra, Mathias, Broqvist, Mari, Gustavsson, Erik, Henriksson, Martin, Juth, Niklas, Sandman, Lars, Solberg, Carl Tollef   +6 more
core   +3 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source